This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alovero, F.
Right arrow Articles by Manzo, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alovero, F.
Right arrow Articles by Manzo, R. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 1998, p. 1495-1498, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Mode of Action of Sulfanilyl Fluoroquinolones

Fabiana Alovero,1 Marcelo Nieto,1 Maria Rosa Mazzieri,1 Rudolf Then,2 and Ruben H. Manzo1,*

Departamento de Farmacia, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina,1 and Pharma Division, Preclinical Research Infectious Diseases, F. Hoffman-La Roche Ltd., Basel, Switzerland2

Received 15 April 1997/Returned for modification 30 May 1997/Accepted 17 March 1998

The mode of action of sulfanilyl fluoroquinolones (NSFQs) was investigated with NSFQ-104, NSFQ-105, and some structurally related compounds. Evidence arising from interactions with p-aminobenzoic acid and trimethoprim suggested that a sulfonamidelike mechanism of action makes little or no contribution to the in vitro activity of NSFQs. NSFQ-105 showed an activity that inhibits gyrase-catalyzed DNA supercoiling that is similar to the activity of other fluoroquinolones. Also, NSFQ-105 uptake was decreased by the presence of Mg2+ and increased by a lower pH. These results indicate that NSFQs having only one ionizable group could exhibit more favorable kinetics of access to the bacterial cell than zwitterionic fluoroquinolones.


* Corresponding author. Mailing address: Departamento de Farmacia, Facultad de Ciencias Químicas, U.N.C. A.P. 4-C.C.61-(5000) Córdoba, Argentina. Phone: 54-51-334163. Fax: 54-51-334127. E-mail: rubmanzo{at}dqo.fcq.unc.edu.ar.


Antimicrobial Agents and Chemotherapy, June 1998, p. 1495-1498, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Hurdle, J. G., O'Neill, A. J., Chopra, I. (2005). Prospects for Aminoacyl-tRNA Synthetase Inhibitors as New Antimicrobial Agents. Antimicrob. Agents Chemother. 49: 4821-4833 [Full Text]  
  • Pan, X.-S., Hamlyn, P. J., Talens-Visconti, R., Alovero, F. L., Manzo, R. H., Fisher, L. M. (2002). Small-Colony Mutants of Staphylococcus aureus Allow Selection of Gyrase-Mediated Resistance to Dual-Target Fluoroquinolones. Antimicrob. Agents Chemother. 46: 2498-2506 [Abstract] [Full Text]  
  • Alovero, F., Barnes, A., Nieto, M., Mazzieri, M. R., Manzo, R. H. (2001). Comparative study of new benzenesulphonamide fluoroquinolones structurally related to ciprofloxacin against selected ciprofloxacin-susceptible and -resistant Gram-positive cocci. J Antimicrob Chemother 48: 709-712 [Abstract] [Full Text]  
  • Piddock, L. J. V., Jin, Y. F., Griggs, D. J. (2001). Effect of hydrophobicity and molecular mass on the accumulation of fluoroquinolones by Staphylococcus aureus. J Antimicrob Chemother 47: 261-270 [Abstract] [Full Text]  
  • Alovero, F. L., Pan, X.-S., Morris, J. E., Manzo, R. H., Fisher, L. M. (2000). Engineering the Specificity of Antibacterial Fluoroquinolones: Benzenesulfonamide Modifications at C-7 of Ciprofloxacin Change Its Primary Target in Streptococcus pneumoniae from Topoisomerase IV to Gyrase. Antimicrob. Agents Chemother. 44: 320-325 [Abstract] [Full Text]